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Abstract
The high molecular weight, multidomain VAR2CSA protein mediating adhesion of Plasmodium falciparum-infected
erythrocytes in the placenta is the leading candidate for a pregnancy malaria vaccine. However, it has been difficult so far to
generate strong and consistent adhesion blocking antibody responses against most single-domain VAR2CSA immunogens.
Recent advances in expression of the full-length recombinant protein showed it binds with much greater specificity and
affinity to chondroitin sulphate A (CSA) than individual VAR2CSA domains. This raises the possibility that a specific CSA
binding pocket(s) is formed in the full length antigen and could be an important target for vaccine development. In this
study, we compared the immunogenicity of a full-length VAR2CSA recombinant protein containing all six Duffy binding-like
(DBL) domains to that of a three-domain construct (DBL4-6) in mice and rabbits. Animals immunized with either
immunogen acquired antibodies reacting with several VAR2CSA individual domains by ELISA, but antibody responses
against the highly conserved DBL4 domain were weaker in animals immunized with full-length DBL1-6 recombinant protein
compared to DBL4-6 recombinant protein. Both immunogens induced cross-reactive antibodies to several heterologous
CSA-binding parasite lines expressing different VAR2CSA orthologues. However, antibodies that inhibited adhesion of
parasites to CSA were only elicited in rabbits immunized with full-length immunogen and inhibition was restricted to the
homologous CSA-binding parasite. These findings demonstrate that partial and full-length VAR2CSA immunogens induce
cross-reactive antibodies, but inhibitory antibody responses to full-length immunogen were highly allele-specific and
variable between animal species.
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Introduction
Pregnancy associated malaria (PAM) is a major cause of poor
mother/child health and increases the risk for maternal anemia,
prematurity, low birth weight and infant morbidity and mortality
[1]. A key feature of PAM is the selective accumulation of
Plasmodium falciparum infected erythrocytes (IEs) in the placenta
mediated by adhesion to chondroitin sulfate A (CSA) [2]. Women
become resistant to pregnancy malaria as they acquire antibodies
to antigens expressed on the surface of IEs that inhibit placental
adhesion and mediate opsonic phagocytosis [3–7].
VAR2CSA belongs to the Plasmodium falciparum erythrocyte
membrane protein 1 (PfEMP1) family encoded by var genes [8–10]
and is the leading PAM vaccine candidate [11–17]. The var gene
family encodes cytoadhesion receptors that facilitate IE binding to
microvascular endothelium through a variety of different host
receptor interactions [18]. Adhesion of IEs to CSA or placental
syncytiotrophoblast leads to specific transcriptional upregulation of
var2csa [14–16] and native VAR2CSA binds to CSA [19].
Furthermore, VAR2CSA appears to be a major target of the
antibody mediated immune response in pregnant women [15,20],
and parasites in which var2csa is genetically disrupted largely lose
the ability to bind to CSA [12,17] and placental syncytiotropho-
blast [21], suggesting it is the primary var gene responsible for
placental sequestration.
Key obstacles to the development of a pregnancy malaria
vaccine are the limited understanding of the targets of inhibitory
antibodies and the best way to induce these responses by
vaccination. VAR2CSA is a large (,350 kDa) and polymorphic
protein with six different Duffy binding-like (DBL) domains and
two other large interdomain regions [14,22]. A significant
component of the acquired antibody response to VAR2CSA
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shared between different VAR2CSA alleles due to extensive gene
mosaicism [22]. This ‘‘patchwork’’ of polymorphic epitopes
appears to contribute to cross-reactive antibody responses between
different CSA-binding parasite lines [23–29], and may facilitate
parasite escape from antibody-dependent protective mechanisms,
as inhibitory epitopes appear to be at least partially strain-
dependent [30–32]. Although CSA-binding properties have been
mapped to several VAR2CSA domains using in vitro binding assays
[13,33,34], recent published data [35,36] casts doubt on the
specificity of single DBL domains for CSA. Recently, the whole
extracellular region of two different VAR2CSA variants were
successfully produced as recombinant proteins and demonstrated
to have significantly higher affinity and specificity for CSA than
individual domains [37,38], indicating that multiple domains may
be involved in binding or come together to form a high affinity
binding site(s). Furthermore, a low resolution structure of full-
length VAR2CSA protein revealed a much more compact
structure than predicted from x-ray crystallographic analysis of
individual domains [38], consistent with three dimensional
modeling that VAR2CSA surface polymorphism is biased with
surprising amounts of invariant surface when individual domains
are considered alone [22,39]. Taken together, interactions
between VAR2CSA domains are likely to occur and single
domain recombinant proteins may display ‘‘off target’’ epitopes
that are buried in the native protein.
While it has been possible to generate surface reactive
antibodies with single-domain VAR2CSA recombinant proteins,
it has been difficult to generate adhesion blocking antibody
responses against individual VAR2CSA domains [23,24,29,40–
42]. To date, the most potent inhibitory antibodies response has
been generated against the highly conserved DBL4 domain [43],
but induction has not been consistently achieved against different
VAR2CSA DBL4 alleles [42,43]. Potential explanations are that
single-domain immunogens may not possess the correct quater-
nary interactions of the native protein or reproduce the high
affinity binding site(s). Thus, there is significant interest in
characterizing larger, multidomain VAR2CSA immunogens that
may better mimic the native protein structure. Whereas nearly all
VAR2CSA vaccination studies have employed single domains, a
recent study suggested that a full-length VAR2CSA recombinant
protein was superior to the best single domain immunogen for
inducing inhibitory antibodies [37]. However, the breadth of
antibody inhibition against different CSA-binding parasite lines
was not examined, and overall there has been limited character-
ization of multidomain VAR2CSA immunogens.
In this study, mice and rabbits were immunized with a partial
length (DBL4-6) or a full-length VAR2CSA (DBL1-6) recombi-
nant protein produced in the human embryonic kidney 293 cell
line. Antibody cross-reactivity was assessed against individual
VAR2CSA domains and on a diverse panel of CSA-binding
parasite lines from different geographic regions for surface
reactivity and binding inhibition activity.
Methods
Ethics statement
All animal work was conducted according to relevant national
and international guidelines. Immunization studies were per-
formed by custom vendors in France (Proteogenix) or the US
(R&R Rabbitry). Animal experiments performed in France were
approved and conducted in accordance with the Institut Pasteur or
Proteogenix Biosafety Committee. Animals were housed under
controlled laboratory conditions by qualified personnel who have
obtained a license to do so from the French Agricultural Ministry
(agreement B 75 15-08 dated May 22, 2008). All researchers
performing animal experiments in this study were directly
responsible for the experimental protocols and obtained individual
licenses from the French Ministry of Agriculture. All animal
experiments performed in the United States were approved by the
Institute Animal and Care Use Committee at Seattle Biomedical
Research Institute and at R&R Rabbitry. Immunizations were
performed at R&R Rabbitry using the approved custom antibody
protocol (Vendor’s PHS assurance # A3982-01 and USDA
registration 91-R-0038).
Recombinant protein expression
The human embryonic kidney cell line (HEK293, Invitrogen)
was used to produce 3D7 DBL4-6 and 3D7 DBL1-6 VAR2CSA
(accession PFL0030c) proteins as soluble, secreted recombinant
proteins [38]. IT4var18 DBL3 and VAR2CSA DBL recombinant
proteins employed in the ELISA assay were produced in Pichia
pastoris as previously described [23,44].
Animal immunization
Immunizations with partial (DBL4-6) and full-length (DBL1-6)
VAR2CSA recombinant proteins were performed at Proteogenix,
France, according to animal immunization guidelines. In brief,
New Zealand White rabbits and Balb/c mice received recombi-
nant protein in TiterMax Gold Adjuvant (Sigma) intradermally for
first immunization and subcutaneously for three boosts. Rabbits
received 50 mg of recombinant protein in first injection and 25 mg
in subsequent injections while mice received 20 mg in first
immunization and 10 mg in subsequent injections. A control
rabbit plasma generated against the NTSDBL1 var O recombi-
nant protein produced in Baculovirus-infected insect cells [45] was a
gift from Odile Mercereau-Puijalon. This immune plasma was
generated by immunizing rabbits with recombinant protein in
Freund’s adjuvant according to French animal immunization
guidelines. Immunizations with IT4var18 DBL3 were performed
at R&R Rabbitry (Washington, USA) according to animal
immunization guidelines. Three New Zealand White rabbits
received 50 mg of antigen in complete Freund’s adjuvant for first
immunization and were boosted with 50 mg of antigen in
incomplete Freund’s adjuvant. Plasma was heat-inactivated for
45 min at 57uC, preabsorbed on normal human red blood cell and
stored at 220uC. IgG antibodies were purified from rabbit plasma
using protein A columns (GE Healthcare, Sweden).
ELISA assay
Rabbit and mouse plasma were tested against the homologous
3D7 DBL1 and 3D7 DBL5 recombinant proteins and heterologous
7G8 DBL1, 7G8 DBL3, 7G8 DBL4, 7G8 DBL5, and 7G8 DBL6
recombinant proteins using ELISA kit from Alpha Diagnostic
International. 96-well ELISA plates (Nunc) were coated with
200 ng recombinant protein and incubated at 4uC overnight. After
blocking, serial diluted plasma from 1/500 to 1/512,000 were
added to antigen-coated wells in duplicate for 1 hr at room
temperature followed by a 1/2000 dilution of HRP-conjugated goat
anti-rabbit or anti-mouse IgG for 1 hr. Plates were washed and
exposed to TMB substrate for 15 min, absorbance read at 450 nm
and analyzed by SOFTmaxPRO version 5. Data were graphed
with 4-pt fit curve and antibody titer calculated at 0.1 OD.
Parasites lines
Plasmodium falciparum parasites were grown in O
+ erythrocytes
and 10% human serum. CSA-binding laboratory isolates,
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[24], 3D7/NF54csa [31], Pf2004csa [24,27] and Pf2006csa
[24,27] were maintained by periodic selection on CSA. Two
CD36-binding negative control parasite lines, A4ultra and ItG-
ICAM-1 were derived from the FCR3/ IT4 parasite genotype.
Parasite genotyping was done with MSP1/MSP2 primers [47].
The primer set for MSP2 nested PCR is not conserved among
Pf2004 and Pf2006 lines which explains the missing band (Figure
S1). Transcription of var2csa was assessed by qRT-PCR using
universal primers as described [23].
Flow cytometry
Mature-stage IEs were grown in O
+ blood and incubated with
rabbit and mouse plasma that had been preabsorbed twice on
uninfected O
+ erythrocytes. For each assay, 10 million erythro-
cytes (5–8% trophozoites) were incubated with a 1/25 or 1/50
dilution of rabbit plasma or a 1/25 dilution of mouse plasma.
Antibodies were detected with Alexafluor 488 conjugated goat
anti-rabbit IgG (Molecular probes) or Alexafluor 488 conjugated
goat anti-mouse IgG (Molecular probes). Samples were analyzed
in an LSRII (Becton Dickinson) and analyzed using FLOWJO 8.1
software (Tree Star Inc). The adjusted mean fluorescence intensity
(MFI) = (IEi-UEi) – (IEp–UEp) where IEi = MFI of infected
erythrocytes following incubation in immune plasma; UEi = MFI
of uninfected erythrocytes following incubation in immune
plasma; IEp= MFI of infected erythrocytes following incubation
in preimmune plasma; UEp = MFI of uninfected erythrocytes
following incubation in preimmune plasma.
Infected erythrocyte adhesion inhibition assay
IE binding was performed on bacterial petri dishes [23]. In
brief, IEs were tested for binding to 10 ml spots of 0.05 mg/ml
bovine CSA (Fluka Biochemika) for all parasite lines except for
3D7csa, which is a weaker binder [48] and required 0.1 mg/ml
CSA. As a control, the ability of VAR2CSA plasma or purified
IgGs to inhibit the binding of CD36-binding parasite lines to
0.05 mg/ml rCD36-Fc (R&D Systems) was employed. Prior to
binding, IEs were enriched via pork gelatin flotation and
parasitemias readjusted to 25% for all parasite lines. Binding
assays were performed with 10 mlo f1 610
7 IEs/ml per spot.
Binding inhibition was calculated as percentage binding in
presence of immune plasma relative to corresponding preimmune
plasma control. Rabbit or mouse polyclonal plasma were tested at
1/5 and 1/10 final dilution or as plasma pool. IgG antibodies were
purified from rabbit plasma using a protein A column (GE
Healthcare, Sweden) and tested at a final concentration of 0.5 or
1.0 mg/ml. Purified IgG were dialyzed against PBS 1X and
concentration determined by BCA assay (Pierce).
Recombinant protein binding inhibition assay
Binding inhibition of full-length, HIS-tagged 3D7 VAR2CSA
recombinant to CSA-proteoglycans was performed using ELISA
plates coated with 100 ml/well of decorin (5 mg/ml) (Sigma) in
PBS, overnight at 4uC. Plates were washed and blocked with PBS
(0.05% Tween20 and 1% BSA) for 1 hr at 37uC. Recombinant
protein 3D7 DBL1-6 (0.2 mg/ml) was pre-incubated with different
concentrations of IgG protein A purified rabbit antibodies (0 to
100 nM) raised against full length 3D7 DBL1-6, 3D7 DBL4-6, or
NTSDBL1 var O as a control for 45 mins at room temperature
under constant shaking, and added to decorin coated plates for
1h ra t3 7 uC. Plates were washed 3X with PBS (0.05% Tween20).
Binding of His-tagged DBL1-6 protein to decorin was detected by
adding 100 ml of an HRP-labeled, anti-His monoclonal antibody
(Qiagen) diluted 1:2000 in blocking buffer for 1 hr at 37uC. TMB
substrate (Biorad) was added to the wells before reading was
measured at 655 nm.
Results
Domain specificity of antibodies generated to partial and
full-length VAR2CSA recombinant proteins
Mice and rabbits were immunized with either 3D7 DBL4-6 or
3D7 DBL1-6 recombinant proteins produced in HEK293 cells.
The purified proteins migrated according to their expected
molecular weight and were purified to higher than 95% purity
[38]. In parallel, three rabbits received the P. pastoris protein
IT4var18 DBL3 as a negative control [44]. To examine domain
specificity, plasma were analyzed by ELISA against homologous
and heterologous VAR2CSA-DBL domains produced in P. pastoris
[44]. As expected, immune plasma to both immunogens reacted
with 3D7 DBL5 recombinant protein, but only the anti-DBL1-6
plasma reacted with 3D7 DBL1 recombinant protein (Figure 1),
indicating that multiple domains were targeted in the full-length
immunogen and that antibody epitopes were not shared between
the DBL4-6 domains and DBL1.
To examine cross-reactive epitopes in VAR2CSA, immune
plasma were tested against five of the six DBL domains from the
7G8 VAR2CSA allele. It has not been possible to express the 7G8
DBL2 domain despite repeated attempts with different domain
boundaries [44]. As shown in Figure 1, immunization with DBL1-
6 recombinant protein induced cross-reactive antibodies to DBL1,
DBL3, DBL4, and DBL5, but there was no or limited cross-
recognition of 7G8 DBL6 in mice or rabbits immunized with
either the DBL1-6 or DBL4-6 recombinant protein. The DBL6
domain is the least conserved of all VAR2CSA domains and
maintains only ,61% identity between alleles [22], which could
contribute to the poor cross-reactivity. Another possible explana-
tion for the poor recognition of VAR2CSA-DBL6 could come
from the capacity of this domain to bind ‘‘non-immune’’ IgM [49],
which could limit access of specific IgGs to their target epitopes.
However, the VAR2CSA-DBL5 has also been reported to bind
non-immune IgM [50], and this would not explain why there was
good recognition of DBL5 in ELISA.
Of interest, both the partial and full-length recombinant
proteins induced strong cross-reactive antibody responses to the
7G8-DBL5 domain. In contrast, the DBL4 domain, which is
the best conserved var2CSA domains and also a target of
inhibitory antibodies induced by immunization of rats [42,43],
was better recognized by all the animals immunized with the
DBL4-6 recombinant protein compared to the DBL1-6
recombinant protein (Figure 1). To a lesser extent, this was
also observed with the DBL6 domain (Figure 1). Thus, the
immunogenicity of the DBL4-6 region differed between partial
and full-length recombinant proteins. Taken together, both
immunogens induced cross-reactive antibodies to one or more
VAR2CSA domains, but there was weaker recognition of the
DBL4 domain in animals immunized with the DBL1-6
recombinant protein.
Immunization with full length or partial VAR2CSA
recombinant protein induces a broad antibody response
to diverse CSA-binding parasite lines
To examine antibody reactivity with native protein, immune
plasma were screened against the homologous 3D7csa parasite
and a panel of six well characterized CSA-binding lines from
diverse worldwide geographic areas, including South America
(7G8), Central America (HB3), and West Africa (Pf2004 and
Pf2006). Two CD36-binding control parasite lines that do not
Antibody Response to Full-Length VAR2CSA
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to serological testing, all of the CSA-binding parasites lines in the
panel were selected for CSA binding and confirmed by qRT-PCR
for expression of the var2csa gene transcript as previously described
[23]. All bound at a high level to CSA, except for the homologous
3D7/NF54 line which adheres to CSA at lower levels [24,48].
Plasmodium falciparum parasites undergo chromosomal deletion or
other changes under in vitro adaptation or long-term cultivation
that can lead to a reduction in cytoadhesion capacity [51,52] and
the 3D7 parasite is known to be poorly cytoadhesive [48]. By
comparing 3D7csa or the parental NF54csa parasite lines that
were originally selected in different laboratories, we identified a
3D7csa parasite line [31] that was strongly reactive with anti-
VAR2CSA antibodies (Figure 2) and bound at a moderate level to
CSA. Like other 3D7csa or NF54csa parasite lines, the parasite
quickly switched expression to a CD36 binding phenotype and it
was necessary to maintain the CSA phenotype with frequent
selections. All of the parasites in the panel were genotyped by PCR
using MSP1/MSP2 primers during the course of the experiments
to prevent cross-contamination (Figure S1) and, in addition, the
authenticity of the 3D7csa parasite line was confirmed by
sequencing PCR products from the highly polymorphic Pfama1
and Pfvar2csa genes (data not shown).
Mouse and rabbit immune plasma against 3D7 DBL4-6 and
3D7 DBL1-6 recombinant proteins reacted by flow cytometry with
homologous 3D7csa parasite line (Figure 2, Table 1), but did not
react with the two CD36-binding control parasite lines (Figure 2,
Table 1). In addition, immune plasma and purified IgG from mice
and rabbits immunized with either the DBL4-6 or DBL1-6
recombinant proteins cross-reacted with multiple CSA-binding
lines in the panel, although some parasite lines were recognized
better than others (Figure 2, Table 1). In contrast, negative control
rabbit antibodies (polyclonal and purified IgG) raised against
IT4var18 DBL3 recombinant protein did not react with any of the
parasites lines (Table 1). Therefore, native VAR2CSA protein at
the IE surface contains cross-reactive epitopes targeted in both the
DBL4-6 and DBL1-6 immunogens.
Immunization with full-length DBL1-6 VAR2CSA
recombinant protein induces strain-specific adhesion
blocking antibodies
To evaluate binding inhibition activity, immune plasma and
purified IgGs were tested in protein binding inhibition assays with
the VAR2CSA DBL1-6 recombinant protein (Figure 3) and in IE
adhesion inhibition assays (Figure 4). There was insufficient mouse
plasma to evaluate in protein binding inhibition assays, so this was
reserved for IE adhesion inhibition assays. The full-length
VAR2CSA recombinant protein (DBL1-6) binds with nanomolar
affinity to the placental CSA-proteoglycan [38]. In the protein
binding inhibition assay, purified rabbit IgG against 3D7-DBL4-6
and a negative control varO DBL1 domain showed no binding
inhibition and only purified IgG against full length 3D7-DBL1-6
inhibited binding of recombinant VAR2CSA DBL1-6 to the CSA-
proteoglycan decorin (Figure 3). Binding was inhibited in a dose-
dependent manner and rabbit 2 had much greater inhibition
activity than rabbit 1 (Figure 3).
In IE adhesion assays, none of the immune plasma from the
individual mice (M1, M2 or M3) or a pool of the three mouse
plasma raised against either the partial or full-length VAR2CSA
immunogens inhibited adhesion of 3D7csa-IEs to CSA (Figure 4A),
although the M1 mouse plasma had much greater surface
reactivity than M2 and M3 (Figure 2). Similar to the protein
binding-inhibition assays, rabbit anti-DBL4-6 plasma or purified
IgG had no inhibitory activity (Figure 4B), and only rabbits
immunized with the DBL1-6 recombinant protein developed
inhibitory antibodies (Figure 4B,C). Inhibition was dose-depen-
dent and rabbit 2 had greater inhibition activity than rabbit 1
(Figure 4B,C), despite the fact that rabbit 2 had lower surface
reactivity by flow cytometry (Table 1). In particular, rabbit 2
immune plasma could inhibit IE adhesion by greater than 80% at
A B
Figure 1. Immunization with DBL4-6 and DBL1-6 VAR2CSA recombinant proteins induces antibodies which target multiple
domains in VAR2CSA. Mouse and rabbit plasma were screened by ELISA against different VAR2CSA recombinant proteins. (A) Rabbit and mouse
plasma against the full-length DBL1-6 recombinant protein were screened against individual VAR2CSA domains, (B) rabbit and mouse plasma against
DBL4-6 recombinant protein were screened against individual VAR2CSA domains. The end point titration of the corresponding preimmune plasma in
ELISA ranged from 0 to 200 at OD 0.1. R1, rabbit #1; R2, rabbit #2; M1, mouse #1; M2, mouse 2; M3, mouse #3.
doi:10.1371/journal.pone.0016622.g001
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rabbit 1 was 60% at 1:5 dilution and was minimal at higher
dilutions (Figure 4B, and data not shown). Similarly, purified IgG
from rabbit 2 had significant inhibitory activity (greater than 70%)
at concentrations as low as 0.25 mg/ml (Figure 4C), while purified
IgG from rabbit 1 had little or no inhibitory activity at 0.5 mg/ml
(Figure 4B).
To evaluate whether rabbit anti-DBL1-6 plasma or purified IgG
could cross-inhibit binding of heterologous CSA-binding parasite
lines expressing different VAR2CSA sequences, cross-inhibition
experiments were performed against different CSA-binding lines.
Despite reacting with these parasite lines by flow cytometry
(Table 1), rabbit anti-DBL1-6 plasma or purified IgG did not
significantly inhibit binding of heterologous CSA-binding lines to
Figure 2. Immunization with DBL4-6 and DBL1-6 VAR2CSA recombinant proteins induces antibodies against the surface of IEs-CSA.
Fluorescence of IEs labeled by rabbit plasma raised against 3D7 DBL1-6 (A) or 3D7 DBL4-6 (B) or mouse plasma raised against 3D7 DBL1-6 (C) or 3D7
DBL4-6 (D) is shown compared to the corresponding preimmune plasma (shaded histograms). In (A) and (B), blue histograms represent labeling with
polyclonal plasma, green histograms show the corresponding purified IgG. In (C) and (D), individual mouse plasma were tested; blue (mouse 1), green
(mouse 2), and orange (mouse 3).
doi:10.1371/journal.pone.0016622.g002
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binding parasite line to the CD36 recombinant protein
(Figure 4B,C). Therefore, immunization with the full-length
VAR2CSA extracellular domain generated inhibitory antibodies
against the homologous strain, but this inhibitory activity was
highly strain-specific and restricted to rabbits.
Discussion
Multiple lines of evidence suggest that VAR2CSA has an
important role in placental binding and support its development
for a pregnancy malaria vaccine, but protein size and polymor-
phism pose a challenge for vaccine development. Although women
exposed to placental infections acquire antibodies that block
adhesion of geographically diverse placental isolates [5], the
specific targets of inhibitory antibodies remain unknown and
inhibitory epitopes appear to be at least partially strain-dependent
[30–32]. VAR2CSA is presumed to be an important target of
inhibitory antibodies, but all of its extracellular domains are under
diversifying selection [22] and it remains unclear which regions
would make the best vaccine immunogen.
Because of its large size and multidomain architecture, initial
vaccine development has concentrated on individual VAR2CSA
DBL domains. While initial studies suggested that DBL2, DBL3,
and DBL6 bind CSA [13], the specificity of these in vitro
interactions has been questioned [36], and it is still unclear
whether multiple individual domains independently engage CSA
Table 1. Cross-reactivity of antibodies against full-length or partial VAR2CSA on lab-adapted lines.
Fluorescence Intensity
*
CSA-binding lines Control lines
Plasma Dilution FCR3 3D7 7G8 Pf2006 Pf2004 HB3A HB3B ITG-ICAM1 A4ultra
3D7 DBL1-6
FB M1 1/25 257 2338 292 136 417 142 141 3 2
FB M2 1/25 133 795 204 82 200 434 478 4 2
FB M3 1/25 257 718 187 121 277 145 132 1 1
FB R1 1/50 392 5921 249 39 123 399 302 3 25
IgG R1 0.11mg/ml 398 1818 148 43 178 603 256 3 20
FB R2 1/50 429 472 165 149 221 397 nd nd 6
IgG R2 0.25mg/ml 527 415 89 88 321 477 nd nd 6
3D7 DBL4-6
FB M1 1/25 139 767 200 102 245 169 157 0 6
FB M2 1/25 169 1558 197 126 279 173 181 0 6
FB M3 1/25 126 1044 251 99 244 190 228 0 0
FB R1 1/50 285 1803 169 53 123 214 123 4 3
IgG R1 0.15mg/ml 322 369 154 59 179 174 186 7 6
IT4var18 DBL3
FB R1 1/25 60 0 10 0 21 38 48 nd 0
FB R2 1/25 0 20 0 0 0 4 0 nd 30
FB R3 1/25 0 0 0 30 0 20 22 nd 5
IgG R1 0.25mg/ml 18 0 0 0 0 0 0 nd 2
IgG R2 0.25mg/ml 0 0 0 0 0 0 0 nd 0
IgG R3 0.25mg/ml 0 0 0 0 0 0 0 nd 7
FB= Final bleed M= Mouse R= Rabbit nd= not done.
*Reactivity is expressed as the adjusted geometric mean of fluorescence intensity.
Values below the negative control anti-IT4var18 DBL3 plasma were considered negative.
doi:10.1371/journal.pone.0016622.t001
Figure 3. Antibodies against the full length protein inhibit 3D7
DBL1-6 VAR2CSA recombinant protein binding to CSA-con-
taining proteoglycans. Purified antibodies were assessed for their
capacity to inhibit protein binding to the CSA-containing proteoglycan
decorin. Protein A purified rabbit IgG were preincubated at different
concentrations with full-length recombinant VAR2CSA protein prior to
addition to wells containing the CSA-containing proteoglycan decorin.
Percent inhibition was calculated relative to the corresponding control
protein A purified IgG raised against varO NTS-DBL1 domain. R1, rabbit
#1; R2, rabbit #2.
doi:10.1371/journal.pone.0016622.g003
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interaction site(s) in the native protein. This adds an extra layer of
complexity in the choice of the immunogen(s) that would prevent
placental sequestration. Whereas individual domains from a
variety of heterologous expression platforms (E. coli, Baculovirus-
infected insect cells, P. pastoris or HEK293) elicit antibodies that
react with CSA-binding isolates [23,24,29,40,41,53], only a few
studies have reported inhibitory antibodies [41–43]. By DNA
immunization, adhesion blocking responses were not observed
against any of the VAR2CSA DBL domains [23]. In contrast,
adhesion blocking responses have been generated to multiple
different DBL domains produced in Baculovirus-infected insect
cells, but the best and most consistent responses were generated in
rats using the FCR3-DBL4 immunogen [42,43]. These antibodies
inhibited the binding of a range of clinical isolates from East and
West Africa, although not all [54]. However, inhibitory antibodies
were not elicited to three other VAR2CSA-DBL4 recombinant
proteins produced in the same Baculovirus system [42,43],
suggesting that inhibitory epitopes may be poorly immunogenic
or difficult to recapitulate with single domain immunogens.
Recent studies show that recombinant proteins based on the
full-length VAR2CSA extracellular region containing all six DBL
domains have ,100,000-fold greater affinity than single DBL
domains for CSA [37,38]. Furthermore, the full-length recombi-
nant protein had a much more compact structure than predicted
from individual domains [38] and a DBL1-6 recombinant protein
from the FCR3-CSA allele induced potent adhesion blocking
antibody responses against the homologous CSA-binding parasite
line that were almost 100-fold higher titer than the FCR3-DBL4
recombinant protein [37]. These findings raised the prospect that
larger, multidomain or full-length proteins may be superior
immunogens to single domains because they more closely mimic
the native VAR2CSA structure.
In this study, we compared the immunogenicity of a 3D7
VAR2CSA DBL4-6 recombinant protein that binds with low
a f f i n i t yt oC S At oa3 D 7V A R 2 C S Af u l l - l e n g t hD B L 1 - 6
recombinant protein that binds with nanomolar affinity to
CSA [38]. Both immunogens induced cross-reactive antibodies
to different CSA-binding parasite lines, indicating they mimic
native protein epitopes. By ELISA, several individual domains
present in each immunogen were targeted by these antibodies.
However, cross-reactive epitopes in the DBL4 domain were less
efficiently targeted in all of the animals immunized with the full-
length immunogen compared to the DBL4-6 recombinant
protein. Furthermore, no inhibitory antibodies were obtained
with the DBL4-6 recombinant protein. Considered with the fact
that DBL4 has higher domain conservation [22] and that anti-
DBL4 antibodies are frequently poorly reactive with the native
protein [23,40,53] this suggests the DBL4 domain may be less
accessible to antibodies in the native protein, which may
contribute to difficulties in consistently generating adhesion
blocking responses against this domain with single or multido-
main immunogens.
Whereas recent work showed that potent adhesion blocking
antibodies were generated in rats immunized with full-length
FCR3-VAR2CSA recombinant protein [37], in this study, only
rabbits and not mice developed inhibitory antibodies to a full-
length 3D7-VAR2CSA protein. The reason why inhibitory
antibodies are not consistently generated to full-length immuno-
gens are unclear, but could relate to the recombinant protein
preparation (FCR3 allele in Baculovirus insect cells versus 3D7 allele
in mammalian cells), the animal species immunized, the adjuvant
employed (Freund’s complete/incomplete adjuvant versus Titer-
Max), or simply the size and complexity of full-length VAR2CSA
immunogens. Our analysis indicates that multiple different DBL
domains are targeted in multi-domain and full-length VAR2CSA
immunogens. Although cross-reactive epitopes were recognized,
antibodies did not cross-inhibit different CSA-binding parasite
lines. These findings are reminiscent of an earlier immunization of
rabbits with CSA-binding IEs [26], in which antibodies reacted
with diverse CSA-binding lines [26] but only inhibited the
homologous parasite isolate [31]. Thus, full length VAR2CSA
recombinant protein is able to reproduce the immune response
induced by CSA binding parasites, confirming the importance of
VARCSA in the acquisition of cross-reactive antibodies. There are
different potential explanations for why adhesion blocking
responses were strain-specific, including that the interaction site(s)
may differ between VAR2CSA alleles or there may be
polymorphism surrounding a related binding site in different
VAR2CSA alleles. Distinguishing between these possibilities will
require a better understanding of how VAR2CSA binds CSA.
In conclusion, these findings demonstrate that immunization
with full-length VAR2CSA extracellular region provides an
experimental approach to generate adhesion blocking responses.
This opens the way for future studies to dissect the mechanism of
adhesion blocking. It further suggests that for larger multidomain
immunogens it may be necessary to develop vaccine strategies that
target the antibody response against critical adhesion blocking
epitopes and that more than one allelic variant may be needed to
cover polymorphism in the parasite population.
Supporting Information
Figure S1 Genotyping of parasite lines with MSP1 and
MSP2 primers. PCR products were run on agarose gels to
distinguish different sized amplicons.
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Figure 4. Immunization with DBL1-6 VAR2CSA recombinant protein induces strain-specific adhesion blocking antibodies. (A)
Adhesion blocking properties of individual mouse plasma (1:5 dilution) or pooled mouse plasma (1:5 dilution) were tested against the 3D7csa and
7G8csa parasite lines. (B) Adhesion blocking properties of immune plasma (1:5 dilution) or purified IgG (0.5 mg/ml) from rabbit #1 immunized with
the DBL4-6 (grey bars) or DBL1-6 recombinant proteins (black bars) were tested against several different CSA-binding parasite lines and two CD36-
binding negative control parasite lines. (C) Dose-dependency adhesion inhibition properties of rabbit #2 anti-3D7 DBL1-6 plasma and purified IgG
tested against 3D7csa parasites. Rabbit #2 anti-3D7 DBL1-6 plasma (1:5 dilution) and purified IgG (0.5 mg/ml) adhesion blocking properties were
tested on four heterologous CSA-binding parasite lines and a CD36-binding negative control parasite line. For antibody adhesion inhibition, CSA-
binding parasite lines were tested for adhesion to CSA and CD36 binding parasite lines were tested for adhesion to CD36. Percent inhibition was
calculated relative to the corresponding preimmune rabbit plasma/purified IgG or a pool of three preimmune mouse plasma. Adhesion inhibition is
the mean of 4 independent spots for all assays.
doi:10.1371/journal.pone.0016622.g004
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